Table 4.
Increase in eNPV per investigational drug for phase III decentralized clinical trials (thousands 2020 USD): variation in combination of screen failure, amendments and cycle time effects
| Factor effects | eNPV delta | eNPV delta as percent of base eNPV (%) | ROI |
|---|---|---|---|
| Amendments only | − $2049 | − 0.2 | − 0.66× |
| Screen failure only | $5226 | 0.4 | 1.67× |
| Cycle time only | $33,323 | 2.6 | 10.66× |
| Screen failure plus amendments | $5460 | 0.4 | 1.75× |
| Amendments plus cycle time | $33,560 | 2.6 | 10.74× |
| Screen failure plus cycle time | $40,921 | 3.1 | 13.09× |
Costs and returns discounted to the start of phase III testing
ROI eNPV delta/Implementation cost